NCT01543958 - Sevelamer for Reducing Endotoxemia and Immune Activation | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

September 30, 2012

Study Completion Date

November 30, 2012

Conditions

HIV-1 Infection

Interventions

DRUG

Sevelamer carbonate

Patients will be administered two 800 mg tablets of Sevelamer carbonate orally three times a day for 8 weeks.

DEVICE

Sevelamer carbonate

Trial Locations (15)

14642

AIDS Care CRS (1108), Rochester

Univ. of Rochester ACTG CRS (1101), Rochester

19104

Hosp. of the Univ. of Pennsylvania CRS (6201), Philadelphia

33136

Univ. of Miami AIDS CRS (901), Miami

35294

Alabama Therapeutics CRS (5801), Birmingham

44106

Case CRS (2501), Cleveland

44109

Metro Health CRS (2503), Cleveland

45267

Univ. of Cincinnati CRS (2401), Cincinnati

60611

Northwestern University CRS (2701), Chicago

63110

Washington University CRS (2101), St Louis

80045

University of Colorado Hospital CRS (6101), Aurora

90095

UCLA CARE Center CRS (601), Los Angeles

90502

Harbor-UCLA Med. Ctr. CRS (603), Torrance

94110

Ucsf Aids Crs (801), San Francisco

02114

Massachusetts General Hospital ACTG CRS (101), Boston

All Listed Sponsors

collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

NETWORK